Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review .
CONCLUSION: The results suggest that the combination of lapatinib plus capecitabine can improve PFS and OS in patients with HER2-positive breast cancer that has progressed on trastuzumab. However, it appears that trastuzumab emtansine provides better treatment outcomes in this context.
.
PMID: 29231164 [PubMed - as supplied by publisher]
Source: International Journal of Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Databases & Libraries | Drugs & Pharmacology | Heart | HER2 | Herceptin | Science | Study | Xeloda